Table 1.
Case characteristics according to body mass index
| Characteristic | Total N (%) or median (range) |
BMI <25 N (%) or median (range) |
BMI≥25 N (%) or median (range) |
P value |
| Age (years) | 68 (27–92) | 68 (27–92) | 67 (33–90) | 0.15 |
| Gender | 0.004 | |||
| Female | 120 (40) | 61 (50) | 59 (34) | |
| Male | 177 (60) | 60 (50) | 117 (66) | |
| Race-ethnicity | 0.21 | |||
| Non-Hispanic white | 227 (76) | 88 (73) | 139 (79) | |
| Other | 70 (24) | 33 (27) | 37 (21) | |
| Cancer type | 0.019 | |||
| Non-small cell lung cancer | 158 (53) | 71 (59) | 87 (49) | |
| Melanoma | 57 (19) | 14 (12) | 43 (24) | |
| Other | 82 (28) | 36 (30) | 46 (26) | |
| Concurrent/sequential therapy | 78 (26) | 38 (31) | 40 (23) | 0.28 |
| Receipt of anti-CTLA4 | 0.6 | |||
| Yes | 39 (13) | 14 (12) | 25 (14) | |
| No | 258 (87) | 107 (88) | 151 (86) | |
| Dosing strategy | 0.16 | |||
| Fixed | 204 (69) | 89 (74) | 115 (65) | |
| Weight-based | 93 (31) | 32 (26) | 61 (35) |
BMI, body mass index; CTLA4, cytotoxic T lymphocyte antigen 4.